1. Search Result
Search Result
Results for "

interleukin?1

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

1

Fluorescent Dye

9

Peptides

3

Inhibitory Antibodies

8

Natural
Products

119

Recombinant Proteins

1

Isotope-Labeled Compounds

12

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123854

    IRAK Inflammation/Immunology
    PF-06426779 is a potent and selective inhibitor of interleukin‑1 receptor associated kinase 4 (IRAK4), with an IC50 of 0.3 nM [1].
    PF-06426779
  • HY-101716

    Interleukin Related Inflammation/Immunology
    RP-54745 is an inhibitor of macrophage stimulation and interleukin-1 production, and a potential antirheumatic compound.
    RP-54745
  • HY-13276

    IRAK Inflammation/Immunology
    IRAK inhibitor 2 is IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor .
    IRAK inhibitor 2
  • HY-106087

    Interleukin Related Inflammation/Immunology
    IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1).
    IX 207-887
  • HY-13278
    IRAK inhibitor 4
    1 Publications Verification

    IRAK Inflammation/Immunology
    IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.
    IRAK inhibitor 4
  • HY-13280

    IRAK Inflammation/Immunology
    IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC50 of 160 nM.
    IRAK inhibitor 6
  • HY-101922

    IRAK Inflammation/Immunology
    IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
    IRAK4-IN-1
  • HY-108822

    Arcalyst; IL 1 Trap; Interleukin 1 Trap

    Interleukin Related Inflammation/Immunology
    Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes [1].
    Rilonacept
  • HY-13277
    IRAK inhibitor 3
    1 Publications Verification

    IRAK Inflammation/Immunology
    IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.
    IRAK inhibitor 3
  • HY-N1120

    (+)-Triptoquinone B

    Interleukin Related Inflammation/Immunology
    Triptoquinone B ((+)-Triptoquinone B), a sesquiterpene alkaloid, is an interleukin-1 inhibitor. Triptoquinone B shows potent inhibitory activities against interleukin 1α and β releases for human peripheral mononuclear cells [1] .
    Triptoquinone B
  • HY-13278A

    IRAK Inflammation/Immunology
    IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor.
    IRAK inhibitor 4 (trans)
  • HY-123195

    Interleukin Related Cancer
    CK-119 is a potent interleukin-1 blocker. CK-119 inhibits the cell growth of fibroblast-like corneal and conjunctival cells, mainly by inhibiting DNA and RNA syntheses [1].
    CK-119
  • HY-N0283R

    Diacerhein(Standard); Diacetylrhein (Standard)

    Interleukin Related Inflammation/Immunology
    Diacerein (Standard) is the analytical standard of Diacerein. This product is intended for research and analytical applications. Diacerein (Diacerhein), a interleukin-1 beta inhibitor, is a slow-acting medicine of the class anthraquinone used to treat joint diseases.
    Diacerein (Standard)
  • HY-N0283S

    Diacerhein-d6; Diacetylrhein-d6

    Interleukin Related Inflammation/Immunology
    Diacerein-d6 is the deuterium labeled Diacerein[1]. Diacerein (Diacerhein), a interleukin-1 beta inhibitor, is a slow-acting medicine of the class anthraquinone used to treat joint diseases[2].
    Diacerein-d6
  • HY-13329
    IRAK-1-4 Inhibitor I
    5+ Cited Publications

    IRAK-1/4 Inhibitor I

    IRAK Inflammation/Immunology
    IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC50s of 0.2 μM and 0.3 μM, respectively.
    IRAK-1-4 Inhibitor I
  • HY-103017
    JH-X-119-01 hydrochloride
    3 Publications Verification

    IRAK Infection
    JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice [1].
    JH-X-119-01 hydrochloride
  • HY-108841
    Raleukin
    Maximum Cited Publications
    27 Publications Verification

    AMG-719; Anakinra

    Interleukin Related Inflammation/Immunology Cancer
    Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects [1] .
    Raleukin
  • HY-139315

    PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 [1].
    PROTAC IRAK4 degrader-4
  • HY-139317

    PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 [1].
    PROTAC IRAK4 degrader-6
  • HY-129967

    Ligands for Target Protein for PROTAC Cancer
    PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) [1].
    PROTAC IRAK4 ligand-1
  • HY-141622

    Interleukin Related Caspase SARS-CoV Infection Inflammation/Immunology
    SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting M pro (IC50 of 30 nM) [1] .
    SDZ 224-015
  • HY-109585

    IRAK Inflammation/Immunology Cancer
    IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment [1].
    IRAK4-IN-7
  • HY-19836
    Zimlovisertib
    5+ Cited Publications

    PF-06650833

    IRAK Inflammation/Immunology
    Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas [1] .
    Zimlovisertib
  • HY-W322573

    Others Inflammation/Immunology
    (R)-Ketoprofen is an orally active nonsteroidal anti-inflammatory drug (NSAID) with analgesic properties. (R)-Ketoprofen does not significantly amplify the increase of inflammatory cytokines (such as tumor necrosis factor (TNF) and interleukin-1 (IL-1)) induced by LPS, but it can inhibit the anti-inflammatory activity of (S)-Ketoprofen [1] .
    (R)-Ketoprofen
  • HY-169057

    IRAK Toll-like Receptor (TLR) Inflammation/Immunology
    BI1543673 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. BI1543673 can reduce the inflammatory response stimulated by TLR4 and TLR7/8 in human lung tissue. BI1543673 can decrease inflammatory signaling in a mouse model of lung inflammation induced by LPS [1].
    BI1543673
  • HY-114181
    IRAK4-IN-4
    1 Publications Verification

    IRAK Cyclic GMP-AMP Synthase Inflammation/Immunology
    IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM [1].
    IRAK4-IN-4
  • HY-77048

    IRAK Inflammation/Immunology
    IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders [1].
    IRAK-4 protein kinase inhibitor 2
  • HY-103291

    Bradykinin Receptor Inflammation/Immunology Endocrinology
    Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings [1].
    Sar-[D-Phe8]-des-Arg9-Bradykinin
  • HY-129966
    PROTAC IRAK4 degrader-1
    1 Publications Verification

    PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively [1].
    PROTAC IRAK4 degrader-1
  • HY-103017A
    JH-X-119-01
    3 Publications Verification

    IRAK Infection Inflammation/Immunology Cancer
    JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice [1]. JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .
    JH-X-119-01
  • HY-150732

    IRAK Inflammation/Immunology
    IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease [1].
    IRAK4-IN-18
  • HY-150733

    IRAK Inflammation/Immunology
    IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease [1].
    IRAK4-IN-19
  • HY-150593

    IRAK Cancer
    IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC50 of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC50 values of 0.2, 0.2, 0.6, and 2.7 μM, respectively [1].
    IRAK4-IN-16
  • HY-111101

    IRAK Cancer
    AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) [1].
    AZ1495
  • HY-162538

    NF-κB IRAK PROTACs Inflammation/Immunology
    LC-MI-3 is an orally active and potent interleukin-1 receptor-associated kinase 4 (IRAK4) PROTAC degrader, with a DC50 of 47.3 nM. LC-MI-3 effectively inhibits the activation of downstream NF-κB signaling. LC-MI-3 can be used for the research of acute and chronic inflammatory skin. (Blue: VHL ligand, Black: linker, Pink: CRBN ligand (HY-14658)) [1].
    LC-MI-3
  • HY-P1110
    AF12198
    1 Publications Verification

    Interleukin Related Inflammation/Immunology
    AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo [1].
    AF12198
  • HY-P2630

    Interleukin Related Inflammation/Immunology
    Suc-YVAD-pNA is a substrate of ICE. Interleukin-1β-converting enzyme (ICE) is a cysteine protease responsible for the cleavage of pre-interleukin-1β (pre-IL-1β) to the mature cytokine and a member of a family of related proteases (the caspases) [1].
    Suc-YVAD-pNA
  • HY-P99246

    MABp1

    Interleukin Related Inflammation/Immunology Cancer
    Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation [1].
    Bermekimab
  • HY-P5890

    Interleukin Related Caspase Neurological Disease
    YVAD-CHO is an interleukin-1β converting enzyme (ICE, caspase 1) inhibitor that can partially delay motoneurone death in lesioned facial nerve mice [1].
    YVAD-CHO
  • HY-N12837

    Others Inflammation/Immunology
    8-Epiloganin can be isolated from Castilleja rubra and has anti-inflammatory properties. 8-Epiloganin inhibits LPS-induced release of pro-inflammatory cytokines, namely tumor necrosis factor-α and interleukin-1β [1].
    8-Epiloganin
  • HY-117432

    NOD-like Receptor (NLR) Inflammation/Immunology
    JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC50 of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages [1].
    JC-171
  • HY-P2628

    Fluorescent Dye Others
    Dabcyl-YVADAPV-EDANS is a fluorogenic interleukin-1β converting enzyme (ICE) substrate for measuring ICE-like protease activity. Dabcyl-YVADAPV-EDANS detects fluorescence at 360 nm excitation and 480 nm emission wavelengths. ICE-like protease is a critical mediator of K + deprivation-induced apoptosis of cerebellar granule neurons [1].
    Dabcyl-YVADAPV-EDANS
  • HY-19676

    VX-740; HMR 3480

    Caspase Inflammation/Immunology
    Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a Ki of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment [1] .
    Pralnacasan
  • HY-N0074
    Byakangelicol
    1 Publications Verification

    COX Inflammation/Immunology
    Byakangelicol, isolated from Angelica dahurica, inhibits interleukin-1beta (IL-1beta) -induced prostaglandin E2 (PGE2) release in A549 cells mediated by suppression of cyclooxygenase-2 (COX-2) expression and the activity of COX-2 enzyme. Byakangelicol has therapeutic potential as an anti-inflammatory agent on airway inflammation [1].
    Byakangelicol
  • HY-126758

    Apoptosis Glutathione Peroxidase Inflammation/Immunology
    Ludartin a sesquiterpene lactone, which can be isolated from the plant Artemisia carruthii Wood. Ludartin reduces the expression of myeloperoxidase and malondialdehyde, enhances the expression of glutathione and superoxide dismutase in spinal cord tissue. Ludartin inhibits neuronal apoptosis. Ludartin inhibits the upregulation of tumor necrosis factor-α, interleukin-1β, and interleukin-6. Ludartin improves the motor function of rats with spinal cord injury [1].
    Ludartin
  • HY-N8936

    Others Inflammation/Immunology
    Narchinol B (Compound 4) is a sesquiter penoid compound. Narchinol B has anti-inflammatory effects. Narchinol B works by inhibiting proinflammatory mediators, including prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) proteins, as well as proinflammatory cytokines, such as interleukin-1b, IL-6, and tumor necrosis factor-α (TNF-α). Narchinol B significantly inhibits LPS-induced overproduction of NO in BV2 cells (IC50=2.43 μM) [1].
    Narchinol B
  • HY-155027

    Dipeptidyl Peptidase TNF Receptor Interleukin Related Inflammation/Immunology Cancer
    DPP-4-IN-8 (compound 27) is a potent and selective DPP4 (dipeptidyl peptidase 4) inhibitor, with a Ki of 0.96 μM. DPP-4-IN-8 blocks the dipeptidase activity of DPP4 in both Caco-2 and HepG-2 cells. DPP-4-IN-8 also dose-dependently suppresses the expression levels of the chemokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) [1].
    DPP-4-IN-8
  • HY-164525

    SC-81490; PF-02881307

    MMP Cancer
    SD-7300 (SC-81490) is an orally active inhibitor of MMP-2, MMP-9, and MMP-13 with Ki values ??of 0.03, 0.01, and 0.03 nM, respectively. SD-7300 can reduce the degradation of extracellular matrix by tumor cells, thereby inhibiting the invasion and metastasis of tumor cells. In addition, SD-7300 is also a dose-dependent inhibitor of mouse corneal angiogenesis and an inhibitor of interleukin-1-induced bovine cartilage degradation. SD-7300 can be used in breast cancer research [1].
    SD-7300
  • HY-N8444

    Interleukin Related Cardiovascular Disease
    Triptoquinone A, an interleukin 1 inhibitor, inhibits endomycin (LPS) or interleukin (IL-1β)-promoted induction of nitric oxide synthase (NOS) in vascular smooth muscle, thereby inhibiting Arg-induced vascular relaxation [1].
    Triptoquinone A
  • HY-148238

    IRAK Inflammation/Immunology
    GNE-2256 (molecule 19) is an orally active IRAK4 (Interleukin 1 receptor associated kinase 4) inhibitor (IRAK4 Ki=1.4 nM; IL-6 IC50=190 nM) [1].
    GNE-2256

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: